risperidone has been researched along with Fatigue in 5 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to characterize the pharmacokinetics and to evaluate the safety of risperidone ISM in patients with schizophrenia or schizoaffective disorder after a single gluteal intramuscular injection at three different dose strengths (50, 75, and 100 mg)." | 9.22 | Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ( Anta, L; Ayani, I; Gutierro, I; Ivanov, M; Llaudó, J; Martínez, J; Morozova, M; Schronen, J, 2016) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 9.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "The aim of this study was to characterize the pharmacokinetics and to evaluate the safety of risperidone ISM in patients with schizophrenia or schizoaffective disorder after a single gluteal intramuscular injection at three different dose strengths (50, 75, and 100 mg)." | 5.22 | Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). ( Anta, L; Ayani, I; Gutierro, I; Ivanov, M; Llaudó, J; Martínez, J; Morozova, M; Schronen, J, 2016) |
| "In this multicenter, double-blind, 16-week, placebo-controlled study conducted at 43 American sites from July 2006 to October 2007, patients with chronic, stable schizophrenia or schizoaffective disorder diagnosed with DSM-IV-TR were randomly assigned to receive aripiprazole (2-15 mg/d) or placebo in addition to a stable regimen of quetiapine (400-800 mg/d) or risperidone (4-8 mg/d)." | 5.14 | A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. ( Assunção-Talbott, S; Carson, WH; Correll, CU; Goff, DC; Kane, JM; Kirkpatrick, B; Marder, SR; Pikalov, A; Sun, W; Vester-Blokland, E, 2009) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "Both patients presented with fatigue, orthostasis, dry mucous membranes, and the unusual finding of miosis." | 1.31 | Atypical presentation of risperidone toxicity. ( Gummin, DD; Hodge, CH; Jewell, M; Leikin, JB, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garzón, M | 3 |
| Angal, S | 3 |
| Rana, M | 3 |
| Llaudó, J | 1 |
| Anta, L | 1 |
| Ayani, I | 1 |
| Martínez, J | 1 |
| Schronen, J | 1 |
| Morozova, M | 1 |
| Ivanov, M | 1 |
| Gutierro, I | 1 |
| Kane, JM | 1 |
| Correll, CU | 1 |
| Goff, DC | 1 |
| Kirkpatrick, B | 1 |
| Marder, SR | 1 |
| Vester-Blokland, E | 1 |
| Sun, W | 1 |
| Carson, WH | 1 |
| Pikalov, A | 1 |
| Assunção-Talbott, S | 1 |
| Gothelf, D | 1 |
| Apter, A | 1 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 1 |
| Weizman, R | 1 |
| Ratzoni, G | 1 |
| Hodge, CH | 1 |
| Jewell, M | 1 |
| Gummin, DD | 1 |
| Leikin, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine o[NCT00325689] | Phase 4 | 323 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for risperidone and Fatigue
2 other studies available for risperidone and Fatigue
| Article | Year |
|---|---|
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Atypical presentation of risperidone toxicity.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Diagnosis, Differential; Dizziness; Drug Ove | 2001 |